On April 24, 2025 Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, reported a Trials in Progress poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), being held from May 30 – June 3, 2025 in Chicago, IL (Press release, Verismo Therapeutics, APR 24, 2025, View Source [SID1234652115]). Poster details are below.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Details:
Abstract Number: TPS5630
Abstract Title: SynKIR-CAR T Cell Advanced Research (STAR)-101 phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma.
Presenting Author: Janos L. Tanyi, M.D., Ph.D., Perelman School of Medicine at the University of Pennsylvania
Session Title: Gynecologic Cancer
Session Date: June 1, 2025, 9:00 AM-12:00 PM CDT
About the KIR-CAR Platform
The KIR-CAR platform is a multi-chain CAR T cell therapy and has been shown in preclinical animal models to be capable of maintaining antitumor T cell activity even in challenging tumor microenvironments. Using NK cell derived KIR and DAP12 split signaling provides a novel combined activation and co-stimulation separate from the usual T cell stimulation pathways. It also enables sustained chimeric receptor expression and improves KIR-CAR T cell long term function. This results in prolonged T cell functional persistence and leads to tumor regression in preclinical models that are resistant to traditional CAR T cell therapies. As a result of decreased T cell exhaustion, KIR-CAR also enables targeting of solid tumors in addition to blood cancers.